HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Insmed (NASDAQ:INSM) and maintained a price target of $52.
September 06, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insmed's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $52.
The reiteration of a 'Buy' rating by a reputable analyst like Andrew Fein from HC Wainwright & Co. is a positive signal for investors. The maintained price target of $52 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100